National Strategic Action Plan for Lung Conditions

Lung disease affects one in four Australians1 and is the second leading cause of death2, yet it struggles to receive the publicity, funding and support required to reduce its impact.

Lung Foundation Australia, together with the support of the Australian Government Department of Health, is working to change the future of lung conditions in Australia by developing the first National Strategic Action Plan for Lung Conditions.

This national plan will define the priorities and actions required to improve lung health and reduce the impact of lung conditions on individuals, the community and the economy.

About the Action Plan

This will be the first National Strategic Action Plan that has been developed to tackle the issue of lung conditions in Australia through a holistic and coordinated approach that is supported by the Australian Government.

The development of a National Strategic Action Plan for Lung Conditions will define the steps required to improve awareness, education, diagnosis, management and research for lung conditions. It will combine the efforts of patients, health professionals, researchers and politicians to acknowledge lung disease as a substantial health burden in Australia, and establish a platform to reduce the impact of lung conditions and improve the outcomes for those affected.

Consultation: Influence the future

In July, Lung Foundation Australia invited a wide range of individuals and organisations to be involved in the first part of a consultation process by completing a survey.

Please see below a summary of the results of our recent survey:

NSAPLC_Summary Report of the Online Survey_August 2018 (436 KB)

A summary of these results, combined with reports on the current state of lung health in Australia, guided our Advisory Group in the development of a draft plan:

Draft for public consultation_NSAPLC_24 September 2018 (1 MB)

We are now inviting the public to provide feedback on the draft Action Plan by Sunday 7 October, 2018.

Complete survey here.

The feedback will be valuable in developing the final draft for submission to the Federal Government.

Advisory Group

An Advisory Group has been established to oversee the consultation process and development of the action plan. The group members are:

  • Christine Jenkins, Respiratory Physician and Clinical Professor of Medicine, Concord Hospital and UNSW, NSW
  • Kerry Hancock, General Practitioner, Chandlers Hill Surgery, SA
  • Anne Holland, Physiotherapist and Professor, Alfred Health Clinical School, LaTrobe University, Vic.
  • Guy Marks, Professor of Respiratory Medicine, South Western Sydney Clinical School, UNSW, NSW
  • Debra Kay, Consumer Engagement Faculty Member of the South Australian Health and Medical Research Institute (SAHMRI)
  • Sara McLaughlin Barrett, Thoracic Liaison Nurse Consultant, Monash Medical Centre, Vic.
  • Adam Jaffe, Respiratory Paediatrician and Professor of Paediatrics, Sydney Children’s Hospital and UNSW, NSW
  • Sarath Ranganathan, Respiratory Physician and Professor, The Royal Children’s Hospital Melbourne and Murdoch Children’s Research Institute, Vic.
  • Tanya Buchanan, Chief Executive Officer, Thoracic Society of Australia and New Zealand, NSW
  • Graeme Maguire, Specialist Physician and Professor, Baker IDI Central Australia and Monash University, Vic.
  • Louise Papps, Respiratory Nurse Consultant, Black Swan Health, WA
  • Kerry Hall, Research Fellow, Menzies Health Institute, Qld
  • Judy Powell, Partnerships Manager, Lung Foundation Australia, Qld

For more information, please contact

1 AIHW, 2016,
2 Lung Disease in Australia, 2014, Woolcock Institute of Medical Research